GRAL stock forecast, quote, news & analysis

Key Takeaways

• GRAIL shares surged roughly 65.8% over the trailing 30 days, climbing from about $80 to a closing price of $132.63.
• The rally was driven primarily by a positive U.S. FDA advisory committee vote on the Galleri multi-cancer early detection test.
• The stock has gained approximately 94% over the past quarter, extending a sustained upward trend.
• Several analysts raised their price targets after the panel vote, with one firm lifting its target to $150.
• GRAIL remains unprofitable on a net basis, and the FDA's final premarket approval decision is still pending.

GRAIL (GRAL) Company Overview and Market Position

GRAIL, Inc. (Nasdaq: GRAL) is a commercial-stage healthcare company focused on detecting cancer early, when it can be treated most effectively. Its flagship product, the Galleri multi-cancer early detection (MCED) test, uses a simple blood draw to screen for more than 50 types of cancer, including several with no recommended screening today. The test is built on a targeted methylation-based platform that combines next-generation sequencing, population-scale clinical studies, and machine learning.

Headquartered in Menlo Park, California, GRAIL was spun off from genomics company Illumina (ILMN) and employs roughly 900 people. The company reported approximately $165 million in trailing-twelve-month revenue but continues to operate at a net loss. Investors follow the stock closely because a successful FDA approval of Galleri could open a large and largely unpenetrated market for blood-based cancer screening.

GRAIL (GRAL) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, GRAL shares rose from a closing price of about $80 on August 28 to $132.63 on September 28, an increase of roughly 65.8%. The move pushed the stock toward the upper end of its 52-week range of $41.50 to $134.42 and was accompanied by a sharp rise in trading volume.

The quarterly picture is even stronger. From a closing level near $68 at the end of June, the stock advanced approximately 94% over the three-month period. The trend has not been a straight line, however; shares briefly pulled back to the low-$60s in early August before the late-quarter catalyst sparked a decisive breakout.

What Drove GRAL Stock Price in the Last 30 Days

The primary catalyst was a favorable vote by the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, which reviewed the premarket approval (PMA) application for Galleri. The panel voted 7-2 in favor of the test's benefits, marking a pivotal step in GRAIL's regulatory pathway and significantly raising market expectations for eventual approval.

The vote triggered a wave of analyst action. Canaccord Genuity raised its price target to $150 from $80 while maintaining a Buy rating, Mizuho lifted its target to $100 from $65 with a Neutral rating, and TD Cowen increased its estimated approval probability to 95%. The combination of the positive panel outcome, upgraded targets, and elevated trading volume drove the stock's rapid ascent from roughly $80 to above $130 in a matter of sessions.

What Drove GRAL Stock Performance Over the Last Quarter

The quarterly advance reflects a broader narrative of regulatory progress rather than any single event. GRAIL submitted its PMA application for Galleri to the FDA in January 2026, supported by data from the PATHFINDER 2 registrational study and the NHS-Galleri trial. Throughout the quarter, investors steadily repriced the stock as the advisory committee meeting approached and as clinical and commercial milestones reinforced the case for approval.

The company also reported continued commercial growth, with full-year 2025 revenue rising roughly 17% year over year, and presented at multiple investor conferences. This accumulation of regulatory and operational catalysts, capped by the September panel vote, underpinned the quarter's sustained upward momentum.

Trending AI Robots

For traders looking to systematize their approach across fast-moving names, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section. These bots vary in strategy, timeframe, and performance metrics, allowing users to explore a range of automated approaches rather than a single method. Investors interested in supplementing their own research with algorithm-based signals can review the curated list to identify bots that align with their objectives and risk tolerance.

GRAL Stock Forecast Drivers: What Investors Should Watch Next

The most important near-term catalyst is the FDA's final decision on the Galleri PMA application, which is expected in the coming months. An approval could validate the MCED market and support commercial expansion, while a delay or adverse outcome would likely weigh on the stock.

Investors should also monitor GRAIL's next quarterly earnings report, which is scheduled for around November 11, 2026, for updates on revenue growth, cash burn, reimbursement progress, and adoption of Galleri. Competitive developments in the broader cancer-screening sector, macroeconomic conditions affecting high-beta healthcare stocks, and any further analyst revisions will also influence the stock's trajectory. As with all high-volatility equities, near-term price swings can be significant.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations